Tranzyme prices IPO, and will use proceeds in part for Phase III ulimorelin trials
This article was originally published in Scrip
Executive Summary
Tranzyme Pharma, which is developing agents for acute and chronic GI motility disorders, has priced its initial public offering. It will seek to raise $54 million through the sale of 13.5 million shares at $4 per share.